Evidence map›Paper›PMID 40474977›Full record

ArticleFrontiers in pharmacology2025

Exploring the molecular mechanisms of huperzine a in the treatment of rosacea through network pharmacology, machine learning, and molecular dynamics simulations.

Xin Luo, Suhan Yang, Lian Zhong, Peng Zhang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xin LuoDepartment of Dermatology, Second Xiangya Hospital, Hunan Key Laboratory of Medical Epigenomics, Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Central South University, Changsha, Hunan, China.
Suhan YangDepartment of Dermatology, Second Xiangya Hospital, Hunan Key Laboratory of Medical Epigenomics, Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Central South University, Changsha, Hunan, China.
Lian ZhongDepartment of Blood Transfusion, Pingxiang People's Hospital, Gannan Medical University, Pingxiang, China.
Peng ZhangDepartment of Dermatology, Second Xiangya Hospital, Hunan Key Laboratory of Medical Epigenomics, Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rosacea is a common chronic inflammatory skin disorder and dysregulation of neuroimmune functions and neurovascular loops play critical roles in the development of rosacea. Huperzine A (Hup A) has several bioactive properties, including anti-inflammatory, antioxidant, and neuroprotective effects. However, the potential roles of Hup A in treating rosacea is unknown. Methods: Network pharmacology, molecular docking, and molecular dynamics simulation techniques has been used to investigate the anti-rosacea mechanisms of Hup A in rosacea. Results: Our results predicted 21 potential anti-rosacea targets of Hup A through public databases. KEGG pathway enrichment analysis revealed that these key targets participated in the regulation of MAPK signaling, NF-kappa B signaling, and PI3KAKT signaling pathways. Further machine learning analysis identified six core targets (BCL2, RXRA, PKN2, XDH, PRKCA, and FAP). Analysis of the GSE65914 dataset showed that XDH was upregulated in rosacea lesions, while BCL2 and RXRA were downregulated, with no significant expression changes of the other genes. Molecular docking results indicated that Hup A could bind to key targets (XDH, BCL2, and RXRA), which were further confirmed by molecular dynamics simulations. Discussion: This study systematically elucidates the potential mechanisms of Hup A in the treatment of rosacea and provides a theoretical basis for its application in rosacea therapy.

Indexed as

huperzine Amachine learningmolecular dynamics simulationnetwork pharmacologyrosacea

Identifiers

PMID40474977
PMCPMC12137240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.